Collaborative Arrangement, Maximum Third Party Share Of Cost

No definition available.

Name:	cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Rights And Obligations, Milestone Payments, Commercialization

+ References

No definition available.

+ Details

Name:	cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Rights And Obligations, Milestone Payments, Development And Regulatory

+ References

No definition available.

+ Details

Name:	cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Direct Transaction Costs

+ References

No definition available.

+ Details

Name:	cdtx_DirectTransactionCosts
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments Related To Collaborative Agreements

+ References

No definition available.

+ Details

Name:	cdtx_PaymentsRelatedToCollaborativeAgreements
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Research And Development Expense, Acquired In Process

+ References

No definition available.

+ Details

Name:	cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability

+ References

No definition available.

+ Details

Name:	cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability
Namespace Prefix:	cdtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479428/808-10-45-3

+ Details

Name:	us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details) - USD ($)		3 Months Ended			37 Months Ended
	Apr. 24, 2024	Mar. 31, 2025	Jun. 30, 2024	Mar. 31, 2024	Apr. 23, 2024	Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from collaborative agreement		$ 0		$ 973,000
Accounts receivable		1,694,000				$ 1,694,000
Janssen Pharmaceuticals, Inc. \| Related Party \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative agreement					$ 27,000,000
Collaborative agreement, maximum cost share					47,800,000
Revenue from collaborative agreement				$ 973,000
Revenue, remaining performance obligation, amount		0
Accounts receivable		$ 0				$ 0
Janssen Pharmaceuticals, Inc. \| License Agreement \| Related Party \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative agreement	$ 85,000,000
Milestone payment obligation, development and regulatory	150,000,000
Milestone payment obligation, commercialization	455,000,000
Acquired in-process research and development			$ 85,400,000
Direct transaction costs			$ 400,000
Janssen Pharmaceuticals, Inc. \| License Agreement \| Upfront Payment \| Related Party \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development	$ 84,900,000
Contract liability					500,000
Janssen Pharmaceuticals, Inc. \| Milestone Achievement \| Related Party \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from collaborative agreement					$ 10,000,000